Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review

International Journal of Antimicrobial Agents

Volumn 35, Issue 3, 2010, Pages 211-218

  Sun, Hsin Yun ^a,b   Singh, Nina ^a,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Breakthrough infection; Candida; Echinocandin; Mycoses

Indexed keywords

ANIDULAFUNGIN; ANTINEOPLASTIC AGENT; CASPOFUNGIN; ECHINOCANDIN; MICAFUNGIN;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ASPERGILLOSIS; CANDIDA; CANDIDIASIS; CRYPTOCOCCOSIS; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; DRUG USE; ESOPHAGITIS; EVIDENCE BASED MEDICINE; FUNGAL STRAIN; FUNGEMIA; FUNGUS ISOLATION; FUSARIOSIS; HUMAN; IMMUNE DEFICIENCY; INCIDENCE; MINIMUM INHIBITORY CONCENTRATION; MUCORMYCOSIS; MYCOSIS; MYELODYSPLASTIC SYNDROME; NONHUMAN; OTITIS; PRIMARY PREVENTION; PRIORITY JOURNAL; SHORT SURVEY; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIFUNGAL AGENTS; CHEMOPREVENTION; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FUNGI; HUMANS; INCIDENCE; MYCOSES;

EID: 73549099328     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2009.09.020     Document Type: Short Survey

References (78)

1. Denning D.W. Echinocandin antifungal drugs. Lancet 362 (2003) 1142-1151
2. Pfaller M.A., Diekema D.J., Ostrosky-Zeichner L., Rex J.H., Alexander B.D., Andes D., et al. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J Clin Microbiol 46 (2008) 2620-2629
3. Pfaller M.A., Boyken L., Hollis R.J., Kroeger J., Messer S.A., Tendolkar S., et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 46 (2008) 150-156
4. De Pauw B., Walsh T.J., Donnelly J.P., Stevens D.A., Edwards J.E., Calandra T., et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46 (2008) 1813-1821
5. Akagi T., Yamaguti K., Kawamura T., Nakumura T., Kubo K., and Takemori H. Breakthrough trichosporonosis in patients with acute myeloid leukemia receiving micafungin. Leuk Lymphoma 47 (2006) 1182-1183
6. Arendrup M.C., Garcia-Effron G., Buzina W., Mortensen K.L., Reiter N., Lundin C., et al. Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. Antimicrob Agents Chemother 53 (2009) 1185-1193
7. Asada N., Uryu H., Koseki M., Takeuchi M., Komatsu M., and Matsue K. Successful treatment of breakthrough Trichosporon asahii fungemia with voriconazole in a patient with acute myeloid leukemia. Clin Infect Dis 43 (2006) e39-41
8. Bayramoglu G., Sonmez M., Tosun I., Aydin K., and Aydin F. Breakthrough Trichosporon asahii fungemia in neutropenic patient with acute leukemia while receiving caspofungin. Infection 36 (2008) 68-70
9. Behre G., Christopeit M., and Weber T. Successful treatment of Candida spp. encephalitis occurring under caspofungin treatment after allogeneic stem cell transplantation. Ann Hematol 88 (2009) 93-94
10. Cheung C., Guo Y., Gialanella P., and Feldmesser M. Development of candidemia on caspofungin therapy: a case report. Infection 34 (2006) 345-348
11. Garcia-Effron G., Kontoyiannis D.P., Lewis R.E., and Perlin D.S. Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. Antimicrob Agents Chemother 52 (2008) 4181-4183
12. Girmenia C., Moleti M.L., Micozzi A., Iori A.P., Barberi W., Foa R., et al. Breakthrough Candida krusei fungemia during fluconazole prophylaxis followed by breakthrough zygomycosis during caspofungin therapy in a patient with severe aplastic anemia who underwent stem cell transplantation. J Clin Microbiol 43 (2005) 5395-5396
13. Goodman D., Pamer E., Jakubowski A., Morris C., and Sepkowitz K. Breakthrough trichosporonosis in a bone marrow transplant recipient receiving caspofungin acetate. Clin Infect Dis 35 (2002) e35-e36
14. Kabbara N., Lacroix C., Peffault de Latour R., Socie G., Ghannoum M., and Ribaud P. Breakthrough C. parapsilosis and C. guilliermondii blood stream infections in allogeneic hematopoietic stem cell transplant recipients receiving long-term caspofungin therapy. Haematologica 93 (2008) 639-640
15. Madureira A., Bergeron A., Lacroix C., Robin M., Rocha V., de Latour R.P., et al. Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin. Int J Antimicrob Agents 30 (2007) 551-554
16. Malhotra P., Shah S.S., Kaplan M., and McGowan J.P. Cryptococcal fungemia in a neutropenic patient with AIDS while receiving caspofungin. J Infect 51 (2005) e181-e183
17. Matsue K., Uryu H., Koseki M., Asada N., and Takeuchi M. Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin. Clin Infect Dis 42 (2006) 753-757
18. Pasquale T., Tomada J.R., Ghannoun M., Dipersio J., and Bonilla H. Emergence of Candida tropicalis resistant to caspofungin. J Antimicrob Chemother 61 (2008) 219
19. Pavie J., Lacroix C., Hermoso D.G., Robin M., Ferry C., Bergeron A., et al. Breakthrough disseminated Aspergillus ustus infection in allogeneic hematopoietic stem cell transplant recipients receiving voriconazole or caspofungin prophylaxis. J Clin Microbiol 43 (2005) 4902-4904
20. Safdar A., O'Brien S., and Kouri I.F. Efficacy and feasibility of aerosolized amphotericin B lipid complex therapy in caspofungin breakthrough pulmonary zygomycosis. Bone Marrow Transplant 34 (2004) 467-468
21. Suzuki K., Nakase K., Ino K., Sugawara Y., Sekine T., and Katayama N. Breakthrough cryptococcosis in a patient with systemic lupus erythematosus (SLE) receiving micafungin. J Infect Chemother 14 (2008) 311-314
22. Suzuki K., Sugawara Y., Sekine T., Nakase K., and Katayama N. Breakthrough disseminated zygomycosis induced massive gastrointestinal bleeding in a patient with acute myeloid leukemia receiving micafungin. J Infect Chemother 15 (2009) 42-45
23. Tascini C., Urbani L., Doria R., Catalano G., Leonildi A., Filipponi F., et al. Breakthrough Fusarium spp fungemia during caspofungin therapy in an ABO-incompatible orthotopic liver transplant patient. J Chemother 21 (2009) 236-238
24. Wetzstein G.A., Green M.R., and Greene J.N. Mould breakthrough in immunosuppressed adults receiving anidulafungin: a report of 2 cases. J Infect 55 (2007) e131-e133
25. Chou L.S., Lewis R.E., Ippoliti C., Champlin R.E., and Kontoyiannis D.P. Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients. Pharmacotherapy 27 (2007) 1644-1650
26. Fortun J., Martin-Davila P., Montejo M., Munoz P., Cisneros J.M., Ramos A., et al. Prophylaxis with caspofungin for invasive fungal infections in high-risk liver transplant recipients. Transplantation 87 (2009) 424-435
27. Hashino S., Morita L., Takahata M., Onozawa M., Nakagawa M., Kawamura T., et al. Administration of micafungin as prophylactic antifungal therapy in patients undergoing allogeneic stem cell transplantation. Int J Hematol 87 (2008) 91-97
28. Hiramatsu Y., Maeda Y., Fujii N., Saito T., Nawa Y., Hara M., et al. Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation. Int J Hematol 88 (2008) 588-595
29. Kishino S., Ohno K., Shimamura T., and Furukawatodo H. Optimal prophylactic dosage and disposition of micafungin in living donor liver recipients. Clin Transplant 18 (2004) 676-680
30. Mattiuzzi G.N., Alvarado G., Giles F.J., Ostrosky-Zeichner L., Cortes J., O'Brien S., et al. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother 50 (2006) 143-147
31. Senn L., Eggimann P., Ksontini R., Pascual A., Demartines N., Bille J., et al. Caspofungin for prevention of intra-abdominal candidiasis in high-risk surgical patients. Intensive Care Med 35 (2009) 903-908
32. van Burik J.A., Ratanatharathorn V., Stepan D.E., Miller C.B., Lipton J.H., Vesole D.H., et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 39 (2004) 1407-1416
33. de Fabritiis P., Spagnoli A., Di Bartolomeo P., Locasciulli A., Cudillo L., Milone G., et al. Efficacy of caspofungin as secondary prophylaxis in patients undergoing allogeneic stem cell transplantation with prior pulmonary and/or systemic fungal infection. Bone Marrow Transplant 40 (2007) 245-249
34. Anttila V.J., Salonen J., Ylipalosaari P., Koivula I., Riikonen P., and Nikoskelainen J. A retrospective nationwide case study on the use of a new antifungal agent: patients treated with caspofungin during 2001-2004 in Finland. Clin Microbiol Infect 13 (2007) 606-612
35. Betts R.F., Nucci M., Talwar D., Gareca M., Queiroz-Telles F., Bedimo R.J., et al. A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis 48 (2009) 1676-1684
36. Brielmaier B.D., Casabar E., Kurtzeborn C.M., McKinnon P.S., and Ritchie D.J. Early clinical experience with anidulafungin at a large tertiary care medical center. Pharmacotherapy 28 (2008) 64-73
37. Cornely O.A., Lasso M., Betts R., Klimko N., Vazquez J., Dobb G., et al. Caspofungin for the treatment of less common forms of invasive candidiasis. J Antimicrob Chemother 60 (2007) 363-369
38. Ellis M., Frampton C., Joseph J., Alizadeh H., Kristensen J., Hauggaard A., et al. An open study of the comparative efficacy and safety of caspofungin and liposomal amphotericin B in treating invasive fungal infections or febrile neutropenia in patients with haematological malignancy. J Med Microbiol 55 (2006) 1357-1365
39. Groetzner J., Kaczmarek I., Wittwer T., Strauch J., Meiser B., Wahlers T., et al. Caspofungin as first-line therapy for the treatment of invasive aspergillosis after thoracic organ transplantation. J Heart Lung Transplant 27 (2008) 1-6
40. Groll A.H., Attarbaschi A., Schuster F.R., Herzog N., Grigull L., Dworzak M.N., et al. Treatment with caspofungin in immunocompromised paediatric patients: a multicentre survey. J Antimicrob Chemother 57 (2006) 527-535
41. Kohno S., Masaoka T., Yamaguchi H., Mori T., Urabe A., Ito A., et al. A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand J Infect Dis 36 (2004) 372-379
42. Krause D.S., Reinhardt J., Vazquez J.A., Reboli A., Goldstein B.P., Wible M., et al. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob Agents Chemother 48 (2004) 2021-2024
43. Kuse E.R., Chetchotisakd P., da Cunha C.A., Ruhnke M., Barrios C., Raghunadharao D., et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 369 (2007) 1519-1527
44. Maertens J., Raad I., Petrikkos G., Boogaerts M., Selleslag D., Petersen F.B., et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 39 (2004) 1563-1571
45. Mora-Duarte J., Betts R., Rotstein C., Colombo A.L., Thompson-Moya L., Smietana J., et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347 (2002) 2020-2029
46. Odio C.M., Araya R., Pinto L.E., Castro C.E., Vasquez S., Alfaro B., et al. Caspofungin therapy of neonates with invasive candidiasis. Pediatr Infect Dis J 23 (2004) 1093-1097
47. Ostrosky-Zeichner L., Kontoyiannis D., Raffalli J., Mullane K.M., Vazquez J., Anaissie E.J., et al. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis 24 (2005) 654-661 Erratum
48. Pappas P.G., Rotstein C.M., Betts R.F., Nucci M., Talwar D., De Waele J.J., et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 45 (2007) 883-893
49. Queiroz-Telles F., Berezin E., Leverger G., Freire A., van der Vyver A., Chotpitayasunondh T., et al. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J 27 (2008) 820-826
50. Reboli A.C., Rotstein C., Pappas P.G., Chapman S.W., Kett D.H., Kumar D., et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 356 (2007) 2472-2482
51. Toubai T., Tanaka J., Ota S., Shigematsu A., Shono Y., Ibata M., et al. Efficacy and safety of micafungin in febrile neutropenic patients treated for hematological malignancies. Intern Med 46 (2007) 3-9
52. Walsh T.J., Teppler H., Donowitz G.R., Maertens J.A., Baden L.R., Dmoszynska A., et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351 (2004) 1391-1402
53. Yanada M., Kiyoi H., Murata M., Suzuki M., Iwai M., Yokozawa T., et al. Micafungin, a novel antifungal agent, as empirical therapy in acute leukemia patients with febrile neutropenia. Intern Med 45 (2006) 259-264
54. Zaoutis T.E., Jafri H.S., Huang L.M., Locatelli F., Barzilai A., Ebell W., et al. A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients. Pediatrics 123 (2009) 877-884
55. Baixench M.T., Aoun N., Desnos-Ollivier M., Garcia-Hermoso D., Bretagne S., Ramires S., et al. Acquired resistance to echinocandins in Candida albicans: case report and review. J Antimicrob Chemother 59 (2007) 1076-1083
56. Cleary J.D., Garcia-Effron G., Chapman S.W., and Perlin D.S. Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment. Antimicrob Agents Chemother 52 (2008) 2263-2265
57. Hakki M., Staab J.F., and Marr K.A. Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob Agents Chemother 50 (2006) 2522-2524
58. Hernandez S., Lopez-Ribot J.L., Najvar L.K., McCarthy D.I., Bocanegra R., and Graybill J.R. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob Agents Chemother 48 (2004) 1382-1383
59. Krogh-Madsen M., Arendrup M.C., Heslet L., and Knudsen J.D. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin Infect Dis 42 (2006) 938-944
60. Laverdiere M., Lalonde R.G., Baril J.G., Sheppard D.C., Park S., and Perlin D.S. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J Antimicrob Chemother 57 (2006) 705-708
61. Miller C.D., Lomaestro B.W., Park S., and Perlin D.S. Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin. Pharmacotherapy 26 (2006) 877-880
62. Moudgal V., Little T., Boikov D., and Vazquez J.A. Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother 49 (2005) 767-769
63. Park S., Kelly R., Kahn J.N., Robles J., Hsu M.J., Register E., et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother 49 (2005) 3264-3273
64. Pelletier R., Alarie I., Lagace R., and Walsh T.J. Emergence of disseminated candidiasis caused by Candida krusei during treatment with caspofungin: case report and review of literature. Med Mycol 43 (2005) 559-564
65. Daneman N., Chan A.K., Poutanen S.M., Rennie R., Sand C., and Porter S. The emergence of caspofungin resistance during treatment of recurrent Candida glabrata candidaemia. Abstracts of the 16th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). 1-4 April 2006, Nice, France. European Society of Clinical Microbiology and Infectious Diseases (2006) Abstract P1204
66. Dodgson K.J., Dodgson A.R., Pujol C., Messer S.A., Soll D.R., and Pfaller M.A. Caspofungin resistant C. glabrata. Abstracts of the 15th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Copenhagen, Denmark, 2-5 April 2006. European Society of Clinical Microbiology and Infectious Diseases (2005) Abstract 1134_02_357
67. Thompson III G.R., Wiederhold N.P., Vallor A.C., Villareal N.C., Lewis II J.S., and Patterson T.F. Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. Antimicrob Agents Chemother 52 (2008) 3783-3785
68. Kahn J.N., Garcia-Effron G., Hsu M.J., Park S., Marr K.A., and Perlin D.S. Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase. Antimicrob Agents Chemother 51 (2007) 1876-1878
69. Perlin D.S. Resistance to echinocandin-class antifungal drugs. Drug Resist Updat 10 (2007) 121-130
70. Hachem R., Hanna H., Kontoyiannis D., Jiang Y., and Raad I. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer 112 (2008) 2493-2499
71. Safdar A., Perlin D.S., and Armstrong D. Hematogenous infections due to Candida parapsilosis: changing trends in fungemic patients at a comprehensive cancer center during the last four decades. Diagn Microbiol Infect Dis 44 (2002) 11-16
72. Pfeiffer C.D., Garcia-Effron G., Zaas A.K., Perfect J.R., Perlin D.S., and Alexander B.D. Breakthrough invasive candidiasis on micafungin. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, CA, 12-15 September 2009 (2009), ASM Press, Washinton, DC Abstract M-1243
73. Kontoyiannis D.P., Lionakis M.S., Lewis R.E., Chamilos G., Healy M., Perego C., et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 191 (2005) 1350-1360
74. Garcia-Effron G., Park S., and Perlin D.S. Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob Agents Chemother 53 (2009) 112-122
75. Garcia-Effron G., Lee S., Park S., Cleary J.D., and Perlin D.S. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-β-d-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob Agents Chemother 53 (2009) 3690-3699
76. Garcia-Effron G., Katiyar S.K., Park S., Edlind T.D., and Perlin D.S. A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob Agents Chemother 52 (2008) 2305-2312
77. Singh N., Limaye A.P., Forrest G., Safdar N., Munoz P., Pursell K., et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 81 (2006) 320-326
78. Reed C., Bryant R., Ibrahim A.S., Edwards Jr. J., Filler S.G., Goldberg R., et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 47 (2008) 364-371